Company Overview
Our Science
- Our Science
- Posters & Publications
Clinical Pipeline
Investors & Media
Contact
- Contact
- Patient Contact
Follow Us
- LinkedIn
- X
- Facebook
- Youtube
- Sign Up for Updates

Company Overview

Company Overview Leadership Team Corporate Governance Partnering Career

Our Science

Our Science Posters & Publications

Clinical Pipeline

Clinical Pipeline Clinical Trials TACTI-004 Phase III

Investors & Media

Investors & Media Press Releases Presentations Events Analyst Reports In the News & Media ASX Announcements SEC Filings Financial Reports FAQ Sign Up for Updates

Contact

Contact Patient Contact

Follow Us

LinkedIn X Facebook Youtube Sign Up for Updates

Bell Potter – Immutep (IMM): Manufacturing process established for IMP761 (autoimmune disease targeting antibody) (Analyst: Dr Tara Speranza)

December 6, 2022

Company Overview
Leadership Team
Corporate Governance
Partnering
Career

Our Science
Posters & Publications

Clinical Pipeline
Clinical Trials

Investors & Media
Press Releases
ASX Announcements
SEC Filings
In the News & Media
Events
Presentations
Analyst Reports
Financial Reports
FAQ

Contact
Patient Contact

© 2025 Immutep. All rights reserved.

Immutep Limited
Level 32, Australia Square
264 George Street
SYDNEY NSW 2000
AUSTRALIA

Ph: +61 2 8315 7003
Fax: +61 2 8569 1880
enquiries@immutep.com

Imprint
Privacy Policy
Terms of Use
Cookie settings

© 2025 Immutep. All rights reserved.

© 2025 Immutep. All rights reserved.

Imprint
Privacy Policy
Terms of Use
Cookie settings